PRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC

COMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival

Pembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial